人福医药(600079) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 6,367,371,531.88, representing a year-on-year increase of 2.28%[4] - The net profit attributable to shareholders decreased by 26.89% to CNY 486,392,045.37 compared to the same period last year[4] - The basic earnings per share for the period was CNY 0.30, down 26.83% year-on-year[4] - The total comprehensive income for Q1 2024 was CNY 613,162,964.98, compared to CNY 862,696,980.10 in Q1 2023, reflecting a decline of 29.0%[18] - Net profit for Q1 2024 was CNY 648,188,795.48, a decrease of 24.7% compared to CNY 861,113,526.51 in Q1 2023[17] - The total comprehensive income for Q1 2024 was 1,046,940,693.40 CNY, compared to 78,627,683.61 CNY in Q1 2023, marking a significant increase[26] Cash Flow - The net cash flow from operating activities was negative at CNY -179,495,908.96, indicating a significant cash outflow[4] - The company reported a significant increase in cash flow from operating activities, with a year-on-year increase of CNY 339 million attributed to sales growth and improved collections[7] - The net cash flow from operating activities was -179,495,908.96, an improvement from -518,077,556.04 in the previous year, indicating a reduction in cash outflow[20] - The company reported a net cash flow from operating activities of -58,027,536.85 CNY in Q1 2024, an improvement from -347,648,507.87 CNY in Q1 2023[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 36,780,555,409.85, an increase of 1.59% from the end of the previous year[5] - The company's total assets amounted to €36.78 billion, an increase from €36.20 billion on December 31, 2023, reflecting a growth of approximately 1.6%[15] - The total liabilities rose to €16.41 billion from €16.11 billion, marking an increase of about 1.9%[14] - The total liabilities amounted to 6,160,701,803.78, slightly up from 6,058,251,485.06, indicating a stable leverage position[23] Equity - The equity attributable to shareholders increased by 2.70% to CNY 17,503,817,763.69 compared to the end of the previous year[5] - The total equity attributable to shareholders increased to €17.50 billion from €17.04 billion, reflecting a growth of approximately 2.7%[14] - The company reported a total equity of 13,805,864,218.58, an increase from 12,753,359,132.53, indicating strong retained earnings growth[24] Investments and Acquisitions - The company acquired assets and 100% equity of Paion Holdings UK Ltd. through its wholly-owned subsidiary in Germany, expanding its product portfolio in Europe[10] - The company plans to acquire assets for €7 million and assume liabilities up to €6 million as part of its strategy to expand in the European pharmaceutical market[11] - The company's long-term equity investments rose to €1.11 billion from €1.09 billion, indicating an increase of approximately 2.9%[13] Expenses - Total operating costs increased to CNY 5,584,162,042.55, up from CNY 5,431,915,788.85, reflecting a rise of 2.8%[16] - Research and development expenses rose to CNY 349,340,705.03, an increase of 22.5% from CNY 285,358,236.04 in the previous year[16] - Sales expenses decreased to CNY 1,203,802,252.65, down from CNY 1,272,496,388.82, indicating a reduction of 5.4%[16] - The company incurred financial expenses of -1,425,780.58 CNY in Q1 2024, a decrease from 25,450,432.19 CNY in Q1 2023, indicating a reduction in financial costs[25] Other Financial Metrics - The weighted average return on equity decreased by 1.50 percentage points to 2.82%[4] - The company reported a decrease in investment income to CNY 16,870,550.16 from CNY 106,784,674.41 in the same period last year[16] - The investment income for Q1 2024 was 1,127,624,014.01 CNY, a substantial increase from 118,262,980.63 CNY in Q1 2023, representing a growth of approximately 853%[25] - The company experienced a foreign exchange loss of CNY 2,989,829.80 in Q1 2024, compared to a loss of CNY 13,352,796.23 in Q1 2023[18] - The company reported a decrease in credit impairment losses to -9,590,072.93 CNY in Q1 2024, compared to 2,767,651.16 CNY in Q1 2023, indicating improved asset quality[25]